TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22563197

Group type: EXPERIMENTAL
Intervention: Reduced volume method (Group A) - did not drink PEG‐ELS the day before; drank 2 L on procedure day.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional volume method (Group B) - drank 2 L PEG‐ELS the day before; drank 1 L on procedure day.
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Reduced volume method (Group A) - 31 subjects.
Number of subjects: 64

Group type: COMPARATOR
Intervention: Conventional volume method (Group B) - 29 subjects.
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both groups received boosters of magnesium citrate.
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Adverse event reported in Group A.
Number of subjects: 64
Study: 20207721

Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP) 15 mg/kg with 100% RDA for SAA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP) with 0% RDA for SAA
Number of subjects: 0

Group type: COMPARATOR
Intervention: 0% RDA for SAA without APAP
Number of subjects: 0
Study: 17684986

Group type: EXPERIMENTAL
Intervention: Controlled epidural analgesia (PCEA) with fentanyl, 2 microg/ml, in 0.2% bupivacaine solution (Group 1)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Bolus infections of fentanyl, 2 microg/ml, in 0.2% bupivacaine solution (Group 2)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Continuous epidural infusion of fentanyl, 2 microg/ml, in 0.2% bupivacaine solution (Group 3)
Number of subjects: 90
Study: 15685505

Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study: 11471080

Group type: EXPERIMENTAL
Intervention: Testing 34 pools of 5 specimens each
Number of subjects: 170

Group type: COMPARATOR
Intervention: Testing all 170 specimens individually
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Pooling 14 specimens per test
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Pooling 2 samples per test
Number of subjects: 170
Study: 9922856

Group type: EXPERIMENTAL
Intervention: Trinipatch (5 mg/24 h and 10 mg/24 h)
Number of subjects: 5078
Study: 7804442

Group type: EXPERIMENTAL
Intervention: Intravenous dexamethasone (4 mg for adults, 2 mg/m2 for children)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Oral dexamethasone (8 mg for adults, 4 mg for children)
Number of subjects: 30
Study: 3051324

Group type: EXPERIMENTAL
Intervention: Pancreatic glucagon (G)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1-21 fragment of pancreatic glucagon (G 1-21)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Physiologic saline (Control)
Number of subjects: 9
Study: 30691671

Group type: EXPERIMENTAL
Intervention: 3 T lung magnetic resonance imaging (MRI)
Number of subjects: 27
Study: 28357975

Group type: EXPERIMENTAL
Intervention: MicroExpression Training Tool (METT), twice weekly for 4 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 22
Study: 26610598

Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 23850170

Group type: EXPERIMENTAL
Intervention: Primary surgery
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 670

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 670

Group type: EXPERIMENTAL
Intervention: Treatment selection based on biomarkers
Number of subjects: 670
Study: 21463154

Group type: EXPERIMENTAL
Intervention: Percutaneous repair
Number of subjects: 279

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 279
Study: 19567516

Group type: EXPERIMENTAL
Intervention: 1.25 mg oral vitamin D(3) (n = 8)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: 1.25 mg oral vitamin D(2) (n = 9)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 17
Study: 16978615

Group type: EXPERIMENTAL
Intervention: Ultrasound, biopsy, blood sampling, In vitro fertilization-ET in the following cycle
Number of subjects: 96

Group type: COMPARATOR
Intervention: Fertile controls
Number of subjects: 96
Study: 15365313

Group type: EXPERIMENTAL
Intervention: Alcohol (1.0 g/kg)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Energy drink (3.57 ml/kg Red Bull)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alcohol + energy drink
Number of subjects: 14

Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 14
Study: 10931079

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (1000 mg) + oral levonorgestrel (250 microg daily)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Testosterone undecanoate (1000 mg) + oral placebo
Number of subjects: 28
Study: 9262873

Group type: EXPERIMENTAL
Intervention: Morning gymnastic time (09:00 to 10:00)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Afternoon gymnastic time (14:00 to 15:00)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Gym (without consideration of time)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Younger subjects (6-7 years)
Number of subjects: 130
Study: 7876402

Group type: EXPERIMENTAL
Intervention: Nabumetone (NAB) 1000 mg daily
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Indomethacin (IND) 50 mg every 12 hours
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sulindac (SUL) 200 mg every 12 hours
Number of subjects: 14
Study: 3277486

Group type: EXPERIMENTAL
Intervention: Nalbuphine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 31770016

Group type: EXPERIMENTAL
Intervention: Scutellaria baicalensis (SB) 3.52 g/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29615378

Group type: EXPERIMENTAL
Intervention: Preoperative fascia iliaca compartment block (FICB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intraoperative surgeon-delivered psoas compartment block (PCB)
Number of subjects: 50
Study: 28654569

Group type: EXPERIMENTAL
Intervention: State Behavioral Scale (SBS)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Withdrawal Assessment Tool‐Version 1 (WAT‐1)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale
Number of subjects: 226
Study: 25794355

Group type: EXPERIMENTAL
Intervention: 5-4-3-2-1 Go! obesity prevention program exposure
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control condition (not specified)
Number of subjects: 246
Study: 23819242

Group type: EXPERIMENTAL
Intervention: Acupoint injection with small dose of fentanyl-droperido mixed liquor
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection with fentanyl-droperido mixed liquor
Number of subjects: 150

Group type: COMPARATOR
Intervention: Subcutaneous injection of 0.9% NaCl
Number of subjects: 150
Study: 21059094

Group type: EXPERIMENTAL
Intervention: Linagliptin 1 mg
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Linagliptin 5 mg
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Linagliptin 10 mg
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Glimepiride (1-3 mg)
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Glimepiride
Number of subjects: 333
Study: 19009498

Group type: EXPERIMENTAL
Intervention: Late gadolinium enhancement (LGE) detected by cardiac magnetic resonance imaging in SSc patients
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (age, sex, and cardiovascular risk factors matched)
Number of subjects: 34
Study: 16996844

Group type: EXPERIMENTAL
Intervention: Enoxaparin (1.5 mg/kg daily for 3 months)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard therapy (angiotensin-converting enzyme inhibitors, beta-blockers, diuretics)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Enoxaparin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 102
Study: 12000508

Group type: EXPERIMENTAL
Intervention: Clotrimazole 1% cream, once daily
Number of subjects: 106

Group type: COMPARATOR
Intervention: Ketoconazole 2% cream, twice daily
Number of subjects: 106
Study: 9509380

Group type: EXPERIMENTAL
Intervention: Yohimbine (5.4 mg orally, 3 times daily, beginning at menses)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 9
Study: 8585398

Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide/Amloride
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 81
Study: 2195890

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of netilmicin (2 g ceftriaxone also administered)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Conventional multiple-daily-dosing regimen of netilmicin (2 g ceftriaxone also administered)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of netilmicin
Number of subjects: 141

Group type: COMPARATOR
Intervention: Conventional doses of netilmicin
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Once-daily doses of netilmicin
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Both dosing strategies
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Once-daily dosing of netilmicin plus ceftriaxone
Number of subjects: 141
Study: 627305

Group type: EXPERIMENTAL
Intervention: Tinidazole (2 g single dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Metronidazole (2 g single dose)
Number of subjects: 60
Study: 6804724

Group type: COMPARATOR
Intervention: EPSDT program (early and periodic screening, diagnosis and treatment)
Number of subjects: 1831
Study: 29594838

Group type: EXPERIMENTAL
Intervention: Severe OSAS group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Moderate OSAS group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mild OSAS group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Posterior ciliary artery (PCA)
Number of subjects: 60
Study: 29659924

Group type: EXPERIMENTAL
Intervention: Pentavalent rotavirus vaccine (PRV)
Number of subjects: 600

Group type: COMPARATOR
Intervention: Control (no PRV)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: PRV
Number of subjects: 600
Study: 27835720

Group type: EXPERIMENTAL
Intervention: Auto-adjusting Positive Airway Pressure (PAP) technology, including auto-bilevel and adaptive servo-ventilation, with compliance > 20 h/wk (56 patients)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Partial PAP users with compliance < 20 h/wk (18 patients)
Number of subjects: 74
Study: 24568890

Group type: EXPERIMENTAL
Intervention: ALA‐PDT
Number of subjects: 14

Group type: COMPARATOR
Intervention: Red light
Number of subjects: 14
Study: 22534258

Group type: EXPERIMENTAL
Intervention: Human milk-based diet (HM40)
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Human milk-based diet (HM100)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control diet (human milk, formula, and bovine-based fortifier)
Number of subjects: 207
Study: 21135795

Group type: EXPERIMENTAL
Intervention: Standardized local treatment combined with compression therapy
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (healers)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Non-healers
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Walking aids usage
Number of subjects: 90
Study: 17917828

Group type: EXPERIMENTAL
Intervention: Adjuvant 5‐fluorouracil (5FU) based chemotherapy
Number of subjects: 1025

Group type: EXPERIMENTAL
Intervention: Lymph node ratio (LNR) in stage III colorectal cancer
Number of subjects: 1025

Group type: COMPARATOR
Intervention: Preoperative radiotherapy in rectal cancer patients
Number of subjects: 1025
Study: 15501929

Group type: EXPERIMENTAL
Intervention: Fluid retention in AMS group
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Plasma Na+ levels
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Urine Na+ and K+ excretion
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Urine Na+-to-K+ ratio
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Antidiuretic hormone levels
Number of subjects: 51
Study: 11899188

Group type: EXPERIMENTAL
Intervention: L-arginine-enriched solution (7.5 g/500 mL)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Standard blood cardioplegic solution (Control)
Number of subjects: 200
Study: 10182416

Group type: EXPERIMENTAL
Intervention: ComputerLink (experimental group)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group (no access to ComputerLink)
Number of subjects: 102
Study: 7621490

Group type: COMPARATOR
Intervention: Topical applications of amine fluoride solution (1%) - Group A (positive control)
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Topical applications of amine fluoride solution (0.5% F) - Group B
Number of subjects: 354

Group type: EXPERIMENTAL
Intervention: Topical applications of amine fluoride solution (0.25% F) - Group C
Number of subjects: 354
Study: 2689396

Group type: EXPERIMENTAL
Intervention: Cisplatin 20 mg/m2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cisplatin 30 mg/m2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cisplatin 40 mg/m2
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cisplatin (all doses) with hyperthermia and radiation
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Cisplatin with hyperthermia and radiation
Number of subjects: 24
Study: 282794

Group type: EXPERIMENTAL
Intervention: 12-lead ECG and systolic time intervals (STI)
Number of subjects: 24
Study: 30803885

Group type: EXPERIMENTAL
Intervention: ADAPT mHealth intervention
Number of subjects: 234

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 234
Study: 26564271

Group type: EXPERIMENTAL
Intervention: Physical exercise program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Non-exercise group (Control)
Number of subjects: 70
Study: 26045114

Group type: EXPERIMENTAL
Intervention: Aroma intervention for preventing nausea and vomiting related to dimethyl sulfoxide in HCT patients
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (no aroma intervention)
Number of subjects: 69
Study: 23458673

Group type: EXPERIMENTAL
Intervention: Anti-cocaine vaccine
Number of subjects: 114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study: 21284801

Group type: EXPERIMENTAL
Intervention: TB-402 0.3 mg kg(‐1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: TB-402 0.6 mg kg(‐1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: TB-402 1.2 mg kg(‐1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Pooled TB-402 groups
Number of subjects: 75
Study: 19222617

Group type: EXPERIMENTAL
Intervention: Lozenge
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tablet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Spray
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gargle
Number of subjects: 0
Study: 17341515

Group type: EXPERIMENTAL
Intervention: Self-administered electronic questionnaire
Number of subjects: 370

Group type: COMPARATOR
Intervention: Self-administered paper-and-pencil questionnaire
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: Orally-administered interview questionnaire
Number of subjects: 370
Study: 15025836

Group type: EXPERIMENTAL
Intervention: eletriptan 20 mg
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: eletriptan 40 mg
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: eletriptan 80 mg
Number of subjects: 321

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 321
Study: 11980683

Group type: EXPERIMENTAL
Intervention: Safety margin of 0 steps above DFT++
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Safety margin of 1 step above DFT++
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Safety margin of 2 steps above DFT++
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Safety margin of 3 steps above DFT++
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Safety margin of 4 steps above DFT++
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: 2 steps above DFT++
Number of subjects: 636

Group type: COMPARATOR
Intervention: Maximal output
Number of subjects: 636

Group type: EXPERIMENTAL
Intervention: Safety margin of 4 to 6 J
Number of subjects: 636
Study: 9794981

Group type: EXPERIMENTAL
Intervention: Ibuprofen syrup (20 mg/mL, 0.25 mL per kg per dose, administered every 6 hours during fever)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo (matching syrup, administered every 6 hours during fever)
Number of subjects: 230

Group type: EXPERIMENTAL
Intervention: Ibuprofen syrup
Number of subjects: 230

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 230
Study: 9098292

Group type: EXPERIMENTAL
Intervention: Silicone oil
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Gas tamponade
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Aphakic/pseudophakic eyes
Number of subjects: 211

Group type: COMPARATOR
Intervention: Postoperative macular pucker
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Large retinal breaks (>= 2 disc diameters)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: Postoperative visual acuity
Number of subjects: 211
Study: 2180481

Group type: EXPERIMENTAL
Intervention: Meals with larger amounts of carbohydrates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meals with simple sugars
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Meals with complex carbohydrates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fat-rich meals
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carbohydrate-rich meals
Number of subjects: 0
Study: 509345

Group type: EXPERIMENTAL
Intervention: Physostigmine administered immediately upon termination of anaesthesia
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Physostigmine administered 30 minutes after the last dose of ketamine
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 111
Study: 31775412

Group type: EXPERIMENTAL
Intervention: Obconic inextensible endoscopic tube
Number of subjects: 91

Group type: COMPARATOR
Intervention: Extensible retractor system
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 91
Study: 30009735

Group type: EXPERIMENTAL
Intervention: Qingfeihuayutongfu prescription (200 mL through nasal feeding, one dose per day for 7 days)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Qingfeihuayutongfu prescription
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 32
Study: 26803474

Group type: EXPERIMENTAL
Intervention: RETeval device using flicker electroretinography (ERG) and pupillography
Number of subjects: 468
Study: 24902473

Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 509

Group type: COMPARATOR
Intervention: Levetiracetam
Number of subjects: 509
Study: 22626799

Group type: EXPERIMENTAL
Intervention: Transhiatal esophagectomy after chemotherapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Transhiatal esophagectomy without chemotherapy
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Transhiatal esophagectomy with chemotherapy
Number of subjects: 30
Study: 19845412

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Psychological interventions (anger and behavioural management, person‐centred planning, nidotherapy)
Number of subjects: 0
Study: 17697105

Group type: EXPERIMENTAL
Intervention: 1% NaOCl
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 5% NaOCl
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: 9% NaOCl
Number of subjects: 8
Study: 15876639

Group type: EXPERIMENTAL
Intervention: Analysis time section A (from stimulus onset to 5 s after the stimulus)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Analysis time section B (from 2 to 7 s after the stimulus)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Analysis time section C (from 4 to 9 s after the stimulus)
Number of subjects: 8
Study: 11738765

Group type: EXPERIMENTAL
Intervention: Anthrax vaccine (AVA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9430010

Group type: EXPERIMENTAL
Intervention: Erythromycin (EM) 250 mg intravenously
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Erythromycin (EM)
Number of subjects: 0
Study: 7892941

Group type: EXPERIMENTAL
Intervention: Normal course of pregnancy
Number of subjects: 87
Study: 2896401

Group type: EXPERIMENTAL
Intervention: Standardized hemodilution treatment (venesection and dextran 40 administration)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control group (no hemodilution treatment)
Number of subjects: 183
Study: 30098962

Group type: EXPERIMENTAL
Intervention: Continuous infusion furosemide
Number of subjects: 90

Group type: COMPARATOR
Intervention: Intermittent bolus furosemide
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Low-dose dopamine
Number of subjects: 90

Group type: COMPARATOR
Intervention: No low-dose dopamine
Number of subjects: 90
Study: 26194361

Group type: EXPERIMENTAL
Intervention: Carboplatin/taxane chemotherapy
Number of subjects: 808
Study: 24150098

Group type: EXPERIMENTAL
Intervention: Bilateral gluteus maximus advancing flap (BGMAF)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Limberg flap (LF)
Number of subjects: 105
Study: 23855560

Group type: EXPERIMENTAL
Intervention: Dialysate sodium 135 mM
Number of subjects: 118

Group type: COMPARATOR
Intervention: Dialysate sodium 140 mM
Number of subjects: 118
Study: 20671038

Group type: EXPERIMENTAL
Intervention: β‐alanine (5 g/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 18971409

Group type: EXPERIMENTAL
Intervention: Peer-based intensive case management
Number of subjects: 137

Group type: COMPARATOR
Intervention: Traditional intensive case management
Number of subjects: 137
Study: 16003201

Group type: EXPERIMENTAL
Intervention: Modified technique using a metallic grid and a modified Steinmann pin with a metallic handle (flag) for targeting.
Number of subjects: 2

Group type: COMPARATOR
Intervention: Traditional freehand technique.
Number of subjects: 2